Funding for this research was provided by:
Innovative Medicines Initiative (DRIVE-AB)
Norwegian Research Council (234608)
U.S. Department of Health and Human Services (IDSEP160030-01-00)
Received: 27 July 2017
Accepted: 19 March 2018
First Online: 5 April 2018
Ethics approval and consent to participate
: Approval was sought for the research portfolio from the Norwegian Committees for Medical and Health Research in December 2015. The Committee determined in February 2016 that ethical approval was unnecessary since the research did not involve patients, animals or other biological substances. Written, informed consent was not obtained from survey respondents. However, they were informed that the data from the survey would be held strictly confidential and that their participation was completely voluntary with no impact on any interaction with the research project DRIVE-AB, its partners, the European Union, or any government.
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.